Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)
ValueMarkers Composite Index
DCF data not available
Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) — VMCI valuation read
Composite valuation read on 300683.SZ: VMCI 41/100 against a Healthcare sector median of 50. The 9-point below-median print is the headline number for Wuhan Hiteck Biological Pharma Co.,Ltd, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for 300683.SZ: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on 300683.SZ: 300683.SZ trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -0.8x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
300683.SZ fell 0.2% over the trailing 7 days, with a -12.4% read on a 30-day basis.
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
Browse More
Key metrics explained
Definitions, formulas, and how ValueMarkers calculates each indicator used in 300683.SZ’s VM Score.
Explore More
Popular Stocks
- Apple (AAPL)Apple value analysis · VMCI score, DCF, MOS
- Microsoft (MSFT)Microsoft value analysis · 120 fundamental indicators
- Alphabet (GOOGL)Alphabet/Google value analysis
- Amazon (AMZN)Amazon intrinsic value and growth profile
- NVIDIA (NVDA)NVIDIA quality, growth, and risk analysis
- Meta Platforms (META)Meta value analysis · VMCI breakdown
- Berkshire Hathaway (BRK.B)Berkshire quality + integrity breakdown
- Johnson & Johnson (JNJ)JNJ dividend quality analysis
- Visa (V)Visa moat, growth, and valuation
- JPMorgan Chase (JPM)JPM financials quality analysis
- Coca-Cola (KO)KO dividend king analysis
- Procter & Gamble (PG)PG dividend king fundamentals
Browse ETFs
- All ETFsTop 100 ETFs by AUM with VMCI-Composite scores
- SPY · S&P 500Broad-market ETF holdings analysis
- VOO · Vanguard S&P 500Low-cost S&P 500 exposure
- QQQ · Nasdaq 100Large-cap growth ETF analysis
- VTI · Total US MarketTotal US equity market ETF
- SCHD · Dividend ETFDividend-focused ETF holdings breakdown
- VYM · High Dividend YieldHigh-yield US dividend ETF
- DGRO · Dividend GrowthDividend growth ETF analysis
- XLK · Tech SectorTechnology sector ETF holdings
- VNQ · Real EstateUS REIT-focused ETF analysis
- GLD · GoldPhysical-gold-backed ETF
- ARKK · Disruptive InnovationThematic growth ETF holdings
Dividend Stocks
- All Dividend Stocks500+ dividend payers with safety scoring
- Dividend Kings50+ years of consecutive dividend growth
- Dividend Aristocrats25+ years of growth · S&P 500 members
- Dividend Contenders10-24 years of dividend growth
- Dividend Challengers5-9 years of dividend growth
- Safe-Yield DividendsQuality > 70 · low-risk dividend payers
- High-Yield DividendsStocks yielding 5%+ with payout health checks
- Dividend Growth10%+ five-year dividend CAGR
- Foreign DividendsNon-US dividend ADRs with VMCI scores
- Coca-Cola (KO) DividendKO dividend deep dive · DRIP projection
- JNJ Dividend AnalysisJohnson & Johnson dividend safety profile
- Procter & Gamble (PG) DividendPG dividend king status
Financial Glossary
- All Definitions120+ value-investing indicators explained
- Piotroski F-ScoreFinancial-strength signal 0-9
- Altman Z-ScoreBankruptcy-distress indicator
- Beneish M-ScoreEarnings-manipulation detection
- Margin of SafetyGraham's discount to intrinsic value
- DCF Intrinsic ValueDiscounted cash-flow valuation
- Graham NumberDefensive-investor fair-value formula
- P/E Ratio (TTM)Trailing price-to-earnings multiple
- EV/EBITDAEnterprise-value to EBITDA multiple
- FCF YieldFree-cash-flow per share / price
- ROICReturn on invested capital · quality signal
- ROIC-WACC SpreadEconomic profit signal
- WACCWeighted average cost of capital
- Dividend YieldAnnual dividend per share / price
- Owner EarningsBuffett's preferred cash-flow metric
Compare Competitors
- All ComparisonsCompare 67+ stock analysis tools
- vs GuruFocusDetailed feature and pricing comparison
- vs TIKRSide-by-side platform comparison
- vs MorningstarCompare analysis capabilities
- vs FinvizScreener comparison and review
- vs Seeking AlphaResearch platform comparison
- vs Simply Wall StVisual analysis comparison
- vs Yahoo FinanceFree tool comparison
- vs ZacksEarnings rank vs fundamental analysis
- vs StockopediaStockRanks vs DCF comparison
- vs Stock RoverPortfolio analytics comparison
- vs KoyfinTerminal-style tool comparison
- vs TradingViewCharting platform comparison
- vs Alpha SpreadValuation tool comparison
- vs WisesheetsExcel/Sheets add-in comparison
- vs MacroaxisData portal vs analysis platform
- vs Old School ValueGraham-style analysis comparison
- vs TIKR TerminalData terminal vs screener comparison